G Kees Hovingh, n/a

Novo Nordisk A/S
Søborg, Denmark, Denmark

Poster(s):

• (P104) SEMAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT OR OBESITY WHO DO NOT HAVE DIABETES
  Friday, October 25, 2024

  1:30 PM – 2:00 PM PT

• (P105) SEMAGLUTIDE, INFLAMMATORY MARKERS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH OVERWEIGHT OR OBESITY IN THE SELECT TRIAL
  Saturday, October 26, 2024

  12:00 PM – 12:30 PM PT

• (P173) ONCE-WEEKLY SEMAGLUTIDE IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION, OBESITY AND TYPE 2 DIABETES: MAIN RESULTS FROM THE STEP-HFPEF DM TRIAL
  Friday, October 25, 2024

  1:30 PM – 2:00 PM PT

• (P178) SEMAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT OR OBESITY AND HEART FAILURE: A PRE-SPECIFIED ANALYSIS FROM THE SELECT TRIAL
  Saturday, October 26, 2024

  1:30 PM – 2:00 PM PT